Home › Compare › PEIMF vs ABBV
PEIMF yields 2486.33% · ABBV yields 3.06%● Live data
📍 PEIMF pulled ahead of the other in Year 1
Combined, PEIMF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of PEIMF + ABBV for your $10,000?
Power Minerals Limited engages in the exploration and development of mineral projects in Australia and Argentina. It primarily explores for lithium, copper, nickel, cobalt, gold, and kaolin deposits. The company holds 100% interest in the Salta Lithium Brine project that comprises 11 leases covering an area of 23,796 hectares located in Salta Province, Argentina; and the Musgrave project that consists of two exploration licenses and eight exploration license applications covering an area of 14,618 square kilometers located in the Musgrave Province, South Australia. It also holds interests in the Eyre Peninsula Kaolin project that consists of three exploration licenses covering an area of 1,413 square kilometers located in South Australia; and the Santa Ines copper-gold project that consists of four mining leases covering 61.4 square kilometers located in Argentina. The company was formerly known as PepinNini Minerals Limited and changed its name to Power Minerals Limited in June 2022. Power Minerals Limited was incorporated in 2002 and is based in Kent Town, Australia.
Full PEIMF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.